1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pediatric Health Care Products and Services Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pediatric Health Care Products and Services Market Analysis and Forecast, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Disease/Disorder/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Pediatric Health Care Products and Services Market Analysis and Forecast, by Disease/Disorder
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease/Disorder, 2023–2031
6.3.1. Allergy and Respiratory
6.3.2. Cancer
6.3.3. Cardiovascular
6.3.4. Central Nervous System
6.3.5. Gastrointestinal
6.3.6. Hormonal Imbalance
6.3.7. Infections
6.3.8. Others
6.4. Market Attractiveness, by Disease/Disorder
7. Global Pediatric Health Care Products and Services Market Analysis and Forecast, by Drug Class
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Class, 2023–2031
7.3.1. Antibiotics
7.3.2. Analgesics
7.3.3. Anti-asthmatics
7.3.4. Antidepressants
7.3.5. Antidiarrheal
7.3.6. Antifungal
7.3.7. Anti-histamines
7.3.8. Antihypertensives
7.3.9. Anti-metabolites
7.3.10. Anti-neoplastic Antibiotics
7.3.11. Antipsychotics
7.3.12. Others
7.3.13. Market Attractiveness, by Drug Class
8. Global Pediatric Health Care Products and Services Market Analysis and Forecast, by Service
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Service, 2023–2031
8.3.1. Child Psychiatry Services
8.3.2. Gastrointestinal Services
8.3.3. Pediatric Cancer Services
8.3.4. Pediatric Diabetes Services
8.3.5. Pediatric Heart Services
8.3.6. Others
8.4. Market Attractiveness, by Service
9. Global Pediatric Health Care Products and Services Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2023–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Pediatric Health Care Products and Services Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Disease/Disorder, 2023–2031
10.2.1. Allergy and Respiratory
10.2.2. Cancer
10.2.3. Cardiovascular
10.2.4. Central Nervous System
10.2.5. Gastrointestinal
10.2.6. Hormonal Imbalance
10.2.7. Infections
10.2.8. Others
10.3. Market Attractiveness, by Disease/Disorder
10.4. Market Value Forecast, by Drug Class, 2023–2031
10.4.1. Antibiotics
10.4.2. Analgesics
10.4.3. Anti-asthmatics
10.4.4. Antidepressants
10.4.5. Antidiarrheal
10.4.6. Antifungal
10.4.7. Anti-histamines
10.4.8. Antihypertensives
10.4.9. Anti-metabolites
10.4.10. Anti-neoplastic Antibiotics
10.4.11. Antipsychotics
10.4.12. Others
10.5. Market Attractiveness, by Drug Class
10.6. Market Value Forecast, by Service, 2023–2031
10.6.1. Child Psychiatry Services
10.6.2. Gastrointestinal Services
10.6.3. Pediatric Cancer Services
10.6.4. Pediatric Diabetes Services
10.6.5. Pediatric Heart Services
10.6.6. Others
10.7. Market Attractiveness, by Service
10.8. Market Value Forecast, by Country, 2023–2031
10.8.1. U.S.
10.8.2. Canada
10.9. Market Attractiveness Analysis
10.9.1. By Disease/Disorder
10.9.2. By Drug Class
10.9.3. By Service
10.9.4. By Country
11. Europe Pediatric Health Care Products and Services Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Disease/Disorder, 2023–2031
11.2.1. Allergy and Respiratory
11.2.2. Cancer
11.2.3. Cardiovascular
11.2.4. Central Nervous System
11.2.5. Gastrointestinal
11.2.6. Hormonal Imbalance
11.2.7. Infections
11.2.8. Others
11.3. Market Attractiveness, by Disease/Disorder
11.4. Market Value Forecast, by Drug Class, 2023–2031
11.4.1. Antibiotics
11.4.2. Analgesics
11.4.3. Anti-asthmatics
11.4.4. Antidepressants
11.4.5. Antidiarrheal
11.4.6. Antifungal
11.4.7. Anti-histamines
11.4.8. Antihypertensives
11.4.9. Anti-metabolites
11.4.10. Anti-neoplastic Antibiotics
11.4.11. Antipsychotics
11.4.12. Others
11.5. Market Attractiveness, by Drug Class
11.6. Market Value Forecast, by Service, 2023–2031
11.6.1. Child Psychiatry Services
11.6.2. Gastrointestinal Services
11.6.3. Pediatric Cancer Services
11.6.4. Pediatric Diabetes Services
11.6.5. Pediatric Heart Services
11.6.6. Others
11.7. Market Attractiveness, by Service
11.8. Market Value Forecast, by Country/Sub-region, 2023–2031
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Market Attractiveness Analysis
11.9.1. By Disease/Disorder
11.9.2. By Drug Class
11.9.3. By Service
11.9.4. By Country/Sub-region
12. Asia Pacific Pediatric Health Care Products and Services Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Disease/Disorder, 2023–2031
12.2.1. Allergy and Respiratory
12.2.2. Cancer
12.2.3. Cardiovascular
12.2.4. Central Nervous System
12.2.5. Gastrointestinal
12.2.6. Hormonal Imbalance
12.2.7. Infections
12.2.8. Others
12.3. Market Attractiveness, by Disease/Disorder
12.4. Market Value Forecast, by Drug Class, 2023–2031
12.4.1. Antibiotics
12.4.2. Analgesics
12.4.3. Anti-asthmatics
12.4.4. Antidepressants
12.4.5. Antidiarrheal
12.4.6. Antifungal
12.4.7. Anti-histamines
12.4.8. Antihypertensives
12.4.9. Anti-metabolites
12.4.10. Anti-neoplastic Antibiotics
12.4.11. Antipsychotics
12.4.12. Others
12.5. Market Attractiveness, by Drug Class
12.6. Market Value Forecast, by Service, 2023–2031
12.6.1. Child Psychiatry Services
12.6.2. Gastrointestinal Services
12.6.3. Pediatric Cancer Services
12.6.4. Pediatric Diabetes Services
12.6.5. Pediatric Heart Services
12.6.6. Others
12.7. Market Attractiveness, by Service
12.8. Market Value Forecast, by Country/Sub-region, 2023–2031
12.8.1. China
12.8.2. Japan
12.8.3. India
12.8.4. Australia & New Zealand
12.8.5. Rest of Asia Pacific
12.9. Market Attractiveness Analysis
12.9.1. By Disease/Disorder
12.9.2. By Drug Class
12.9.3. By Service
12.9.4. By Country/Sub-region
13. Latin America Pediatric Health Care Products and Services Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Disease/Disorder, 2023–2031
13.2.1. Allergy and Respiratory
13.2.2. Cancer
13.2.3. Cardiovascular
13.2.4. Central Nervous System
13.2.5. Gastrointestinal
13.2.6. Hormonal Imbalance
13.2.7. Infections
13.2.8. Others
13.3. Market Attractiveness, by Disease/Disorder
13.4. Market Value Forecast, by Drug Class, 2023–2031
13.4.1. Antibiotics
13.4.2. Analgesics
13.4.3. Anti-asthmatics
13.4.4. Antidepressants
13.4.5. Antidiarrheal
13.4.6. Antifungal
13.4.7. Anti-histamines
13.4.8. Antihypertensives
13.4.9. Anti-metabolites
13.4.10. Anti-neoplastic Antibiotics
13.4.11. Antipsychotics
13.4.12. Others
13.5. Market Attractiveness, by Drug Class
13.6. Market Value Forecast, by Service, 2023–2031
13.6.1. Child Psychiatry Services
13.6.2. Gastrointestinal Services
13.6.3. Pediatric Cancer Services
13.6.4. Pediatric Diabetes Services
13.6.5. Pediatric Heart Services
13.6.6. Others
13.7. Market Attractiveness, by Service
13.8. Market Value Forecast, by Country/Sub-region, 2023–2031
13.8.1. Brazil
13.8.2. Mexico
13.8.3. Rest of Latin America
13.9. Market Attractiveness Analysis
13.9.1. By Disease/Disorder
13.9.2. By Drug Class
13.9.3. By Service
13.9.4. By Country/Sub-region
14. Middle East & Africa Pediatric Health Care Products and Services Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Disease/Disorder, 2023–2031
14.2.1. Allergy and Respiratory
14.2.2. Cancer
14.2.3. Cardiovascular
14.2.4. Central Nervous System
14.2.5. Gastrointestinal
14.2.6. Hormonal Imbalance
14.2.7. Infections
14.2.8. Others
14.3. Market Attractiveness, by Disease/Disorder
14.4. Market Value Forecast, by Drug Class, 2023–2031
14.4.1. Antibiotics
14.4.2. Analgesics
14.4.3. Anti-asthmatics
14.4.4. Antidepressants
14.4.5. Antidiarrheal
14.4.6. Antifungal
14.4.7. Anti-histamines
14.4.8. Antihypertensives
14.4.9. Anti-metabolites
14.4.10. Anti-neoplastic Antibiotics
14.4.11. Antipsychotics
14.4.12. Others
14.5. Market Attractiveness, by Drug Class
14.6. Market Value Forecast, by Service, 2023–2031
14.6.1. Child Psychiatry Services
14.6.2. Gastrointestinal Services
14.6.3. Pediatric Cancer Services
14.6.4. Pediatric Diabetes Services
14.6.5. Pediatric Heart Services
14.6.6. Others
14.7. Market Attractiveness, by Service
14.8. Market Value Forecast, by Country/Sub-region, 2023–2031
14.8.1. GCC Countries
14.8.2. South Africa
14.8.3. Rest of Middle East & Africa
14.9. Market Attractiveness Analysis
14.9.1. By Disease/Disorder
14.9.2. By Drug Class
14.9.3. By Service
14.9.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. AstraZeneca plc
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Disease/Disorder Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Boehringer Ingelheim GmbH
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Disease/Disorder Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Eisai Co., Ltd.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Disease/Disorder Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Gilead Sciences, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Disease/Disorder Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. GlaxoSmithKline plc
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Disease/Disorder Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Merck & Co., Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Disease/Disorder Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Mylan N.V.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Disease/Disorder Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Novartis AG
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Disease/Disorder Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Pediapharm, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Disease/Disorder Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Pfizer, Inc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Disease/Disorder Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Sanofi S.A.
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Disease/Disorder Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/